Agenus releases corporate overview presentation on botensilimab-balstilimab neoadjuvant colon cancer data

• Agenus published a corporate overview highlighting botensilimab with balstilimab in neoadjuvant MSS colon cancer.
• IST data from NEST and UNICORN in 38 MSS patients showed about 30% pCR, about 40% MPR, 100% EFS at 9-18 months.
• Registrational Phase 3 “ROBBIN” planned with FDA alignment, n=850, 1:1 randomization, primary endpoint EFS, first patient in by Q1 2027.
• US addressable market estimated above $7 billion, based on about 38,000 eligible high-risk Stage II and Stage III MSS patients annually.
• PIPE financing in July 2026 expected to fund ROBBIN costs and operations through end-2031, assuming full warrant exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.